Person:
GÜLLÜLÜ, MUSTAFA

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

GÜLLÜLÜ

First Name

MUSTAFA

Name

Search Results

Now showing 1 - 10 of 31
  • Publication
    Association of morning blood pressure surge (mbps) with left ventricular hypertrophy in autosomal dominant polycystic kidney disease (ADPKD): Across sectional study
    (Oxford Univ Press, 2016-05-01) Sağ, Saim; Yıldız, Abdulmecit; Ersoy, Alparslan; Ocakoğlu, Gökhan; Oruç, Ayşegül; Güngören, Fatih; Ayar, Yavuz; Gül, Cuma Bülent; Güllülü, Sümeyye; Güllülü, Mustafa; Sağ, Saim; YILDIZ, ABDULMECİT; ERSOY, ALPARSLAN; OCAKOĞLU, GÖKHAN; ORUÇ, AYŞEGÜL; Güngören, Fatih; Ayar, Yavuz; GÜL, CUMA BÜLENT; GÜLLÜLÜ, NAZMİYE SÜMEYYE; GÜLLÜLÜ, MUSTAFA; Tıp Fakültesi; Kardioloji Bölümü; 0000-0002-1114-6051; 0000-0002-0342-9692; 0000-0003-4607-9220; 0000-0003-2467-9356; AAH-5180-2021; AGF-0767-2022; AAW-9185-2020; AAH-5054-2021; O-9948-2015; AAA-3163-2021; HLG-6346-2023; AAH-4002-2021; A-7063-2018; GSE-0029-2022; HIG-9032-2022; JGR-6552-2023; CTG-8811-2022
  • Publication
    Screening for fabry disease in patients who underwent renal biopsy and identification of a novel mutation
    (Aves, 2021-04-01) Oruç, Ayşegül; Yıldız, Abdulmecit; Akgür, Suat; Aydın, Mehmet Fethullah; Ersoy, Alparslan; Yavuz, Mahmut; Dilek, Kamil; Güllülü, Mustafa; ORUÇ, AYŞEGÜL; YILDIZ, ABDULMECİT; AKGÜR, SUAT; Aydın, Mehmet Fethullah; ERSOY, ALPARSLAN; YAVUZ, MAHMUT; DİLEK, KAMİL; GÜLLÜLÜ, MUSTAFA; Tıp Fakültesi; Nefroloji Ana Bilim Dalı; 0000-0002-0342-9692; 0000-0002-5665-7402; AAJ-8220-2020; AAH-4002-2021; HIG-9032-2022; EJA-1761-2022; CPX-5894-2022; EHM-7377-2022; EUF-5229-2022; JGS-9425-2023
    Background: The X-linked Fabry disease (FD) with lysosomal storage of globotriaosylceramide (Gb3) due to alpha-galactosidase deficiency contributes to nephropathy consisting of proteinuria and renal failure eventually. Early initiation of the enzyme replacement therapy promises favorable renal outcomes. With the importance of early diagnosis, we screened FD among proteinuric patients in whom biopsy findings revealed Fabry nephropathy.Methods: Patients with light microscopic biopsy findings of vacuolated cells, focal and/or segmental glomerular sclerosis, tubular atrophy, and interstitial fibrosis were not associated with particular etiology, the presence of acro-paresthesia, angiokeratomas, and cornea verticillata, stroke history younger than 50 years, family history of renal failure with no cardiovascular risk factors were screened. Fifty-three of 308 consecutive adult patients (45.34 +/- 15.23 years old, 60.1% male) who underwent renal biopsy because of proteinuria were enrolled in the study. Screening for FD was performed by assessing alpha-Gal A activity in dried blood spots (DBS) for males and by genetic testing for females.Results: Fifty-three patients (39.94 +/- 11.97 years, 69.8% male) who underwent renal biopsy were screened. Laboratory findings revealed mean serum creatinine of 1.44 +/- 1.06 mg/dL, mean estimated glomerular filtration rate of 78.31 +/- 39.89 mL/min/1.73 m(2), and mean proteinuria of 4.32 +/- 3 g/day, whereas the females genetic screening was negative. Two of 37 males had low enzyme activity (<0.1 micmol/L/h) and confirmed FD by genetic analysis in whom one had a novel mutation of GLA gene (c.(1047G>A) p.(Trp349*)).Conclusion: It is worth noting that FD screening in patients with proteinuria, in whom vacuolated cells, mesangial expansion, glomerulosclerosis, interstitial fibrosis, and tubular atrophy of unknown etiology, are present in the renal biopsy either with or without a family history of kidney disease.
  • Publication
    A family with IgA nephropathy and hereditary lymphoedema praecox
    (Wiley, 2002-05-01) Usta, M; Dilek, Kamil; Ersoy, Ahmet; Alper, E; Özbek, Serhat; Özdemir, Bülent; Filiz, G; Yavuz, M; Güllülü, Mustafa; Yurtkuran, Merih; Usta, M; DİLEK, KAMİL; Ersoy, Ahmet; Alper, E; ÖZBEK, SERHAT; ÖZDEMİR, BÜLENT; Filiz, G; Yavuz, M; GÜLLÜLÜ, MUSTAFA; Yurtkuran, Merih; Uludağ Üniversitesi Tıp Fakültesi; Nefroloji Bölümü; 0000-0003-3427-8337; 0009-0001-9179-9107; HYD-3798-2023; CNY-9323-2022; GXG-1656-2022; CCY-8570-2022; FTG-3544-2022; JHE-3353-2023; EVQ-8652-2022; HJG-9929-2022; JGS-9425-2023; GLB-5791-2022
    Immunoglobulin A (IgA) nephropathy is the most common primary glomerulonephritis worldwide. The pathogenesis is still unknown and treatment has not yet been established. Rarely it can be associated with other disorders. Its association with hereditary lymphoedema is not reported before. We report four patients, a 60-year-old father, his two sons and his daughter, with hereditary lymphoedema. The family had nine members and in four of them lymphoedema was evident. The other members had neither lymphoedema nor IgA nephropathy. This is the first report of IgA nephropathy in association with hereditary lymphoedema.
  • Publication
    Efficacy of tacrolimus in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatments
    (Türk Nefroloji Diyaliz Transplantasyon Dergisi, 2011-01-01) Usta, Mehmet; Ersoy, Alparslan; Gül, Cuma Bülent; Kahvecioğlu, Serdar; Akdağ, İbrahim; Güllülü, Mustafa; Yavuz, Mahmut; Dilek, Kamil; Yurtkuran, Mustafa; ERSOY, ALPARSLAN; GÜL, CUMA BÜLENT; GÜLLÜLÜ, MUSTAFA; YAVUZ, MAHMUT; DİLEK, KAMİL; Yurtkuran, Mustafa; Tıp Fakültesi; Nefroloji Ana Bilim Dalı; 0000-0002-0710-0923 ; 0000-0003-2467-9356; AAH-5054-2021; A-7063-2018; JGS-9425-2023; EHM-7377-2022; EUF-5229-2022; EGT-2006-2022
    OBJECTIVE: We investigated the efficacy and safety of tacrolimus in patients with primary focal segmental glomerulosclerosis (FSGS) resistant to treatment in this study.MATERIAL and METHODS: This prospective study included 9 patients (5 female/4 male) with FSGS resistant to steroids. Their immunosuppressive treatments except corticosteroids were stopped at least six months previously. Tacrolimus (4 mg/day) treatment was administered. The daily urinary protein excretion, serum creatinine, albumin and total cholesterol values were measured before and after treatment.RESULTS: The mean level of daily urinary protein excretion, serum creatinine and serum albumin at the baseline was 4.7 +/- 3.3 g/day, 1.2 +/- 0.6 mg/dL, and 3.5 +/- 0.7 g/dL, respectively. The daily urinary protein excretion significantly reduced from the 1st month of the treatment. At the 6th month, complete remission was achieved in 3 patients (33%) and partial remission in 2 patients (22%). 3 patients were resistant to the treatment. There was no difference in serum albumin, creatinine and cholesterol levels after the treatment when compared to the baseline levels.CONCLU SION: Tacrolimus is a safe and effective treatment in patients with FSGS resistant to treatment. However, the tendency to relapse in all patients who have complete or partial remission when the treatment was withdrawn demonstrates dependence on treatment.
  • Publication
    Immunosuppressive treatment results in patients with primary iga nephropathy in Turkiye: A nationwide study
    (Oxford Univ Press, 2023-06-01) Sümnü, Abdullah; Türkmen, Aydın; Baştürk, Taner; Cebeci, Egemen; Turgutalp, Kenan; Çetinkaya, Hakkı; Kibar, Müge Üzerk; Seyahi, Nurhan; Tatar, Erhan; Ergül, Metin; Derici, Ülver; Aylı, Deniz; Pınar, Musa; Bakar, Betül; Kazancıoğlu, Rümeyza; Dirim, Ahmet Burak; Yılmaz, Zülfikar; Türkmen, Kültiğin; Tunca, Onur; Koç, Mehmet; Kutlay, Sim; Mlicozkadioğlu, Hasan; Azak, Alper; Boztepe, Burcu; Ustundağ, Sedat; Öztürk, Seda Şafak; Ünsal, Abdülkadir; Karadağ, Serhat; Şahin, Gülizar Manga; Yenigün, Ezgi Coşkun; Eren, Necmi; Güllülü, Mustafa; GÜLLÜLÜ, MUSTAFA; Oruç, Ayşegül; ORUÇ, AYŞEGÜL; Yıldız, Abdülmecit; YILDIZ, ABDULMECİT; Tıp Fakültesi; Nefroloji Ana Bilim Dalı; 0000-0002-0342-9692; AAH-4002-2021; HIG-9032-2022; JCR-8518-2023
  • Publication
    The effects of the renin-angiotensin-aldosterone system blockers on serum ischemia-modified albumin levels in autosomal dominant polycystic kidney disease
    (Springer London Ltd, 2022-01-23) Ermurat, Selime; Güllülü, Mustafa; Sarandöl, Emre; GÜLLÜLÜ, MUSTAFA; SARANDÖL, EMRE; Tıp Fakültesi; Nefroloji Ana Bilim Dalı; JGS-9425-2023; DXM-3644-2022
    Background Among one of the common hereditary causes of chronic kidney disease is autosomal-dominant polycystic kidney disease (ADPKD), and its incidence rate is reported as one between 500 and 1.000 individuals. The most common complications of ADPKD are hypertension (HT) and end-stage renal disease (ESRD). HT occurring in the early stage of ADPKD leads to deteriorations in renal function. Aims It was aimed to investigate the ischemia-modified albumin (IMA) levels and the effect of renin-angiotensin-aldosterone system (RAAS) blockers on serum IMA levels in patients with ADPKD. Methods One hundred and fifteen patients were included as ADPKD (n = 50), HT (n = 35), and healthy control (HC) groups (n = 30). Patients with ADPKD and HT were divided into two subgroups as RAAS blocker-users and non-users. Results Serum IMA levels were detected as 0.42 (0.17-0.80) in ADPKD and 0.28 (0.04-0.51) in HT and 0.36 (0.22-0.56) in HC groups as absorbance units (ABSU), and the highest serum IMA level was seen in Group ADPKD. Serum IMA levels were 0.33 +/- 0.14 in RAAS blocker-users and 0.41 +/- 0.11 ABSU in non-users with ADPKD. Serum IMA levels were witnessed to be significantly lower in RAAS blocker-users in Groups ADPKD (p = 0.038) and HT (p = 0.004), compared to non-users. Given basal and 6-month values of those with ADPKD, the levels of serum IMA within 6 months were significantly lower (p = 0.002). Conclusions We consider that serum IM levels should be assessed in oxidative stress (OS)-related conditions, such as ADPKD, and RAAS blockers may be effective in reducing serum IMA levels in ADPKD and HT patients.
  • Publication
    The evaluation of amyloidosis cases with renal involvement: A single-center experience
    (Türk Nefroloji Diyaliz Transplantasyon Dergisi, 2015-01-01) Ayar, Yavuz; Ersoy, Alparslan; Yıldız, Abdülmecit; Işıktas Sayılar, Emel; Çelikçi, Sedat; Arslan, İsmail; Öksüz, Mustafa Ferhat; Güllülü, Mustafa; Ayar, Yavuz; ERSOY, ALPARSLAN; Işıktas Sayılar, Emel; Çelikçi, Sedat; Arslan, İsmail; Öksüz, Mustafa Ferhat; GÜLLÜLÜ, MUSTAFA; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; 0000-0003-4607-9220; 0000-0002-1539-9216; AGF-0767-2022; AAH-5054-2021; FAZ-9764-2022; JIF-8775-2023; JML-0742-2023; KQP-2558-2024; JGS-9425-2023
    OBJECTIVE: Amyloidosis is a chronic disease associated with proteinuria and can progress to renal failure. The diagnosis and treatment of the underlying cause is therefore important. In this study at a university hospital, the diagnosis of amyloidosis patients with renal biopsies was evaluated retrospectively.MATERIAL and METHODS: 69 (42 males, 27 females, mean age: 51.7 +/- 14.8 years) patients were diagnosed with amyloidosis with renal biopsy. Indications for biopsy was nephrotic syndrome in 42 patients (60.9%), nephritic syndrome in 27 (39.1%) and renal dysfunction with proteinuria in 31 (44.9%).RESULTS: The most common causes of secondary amyloidosis were Familial Mediterranean Fever in 17 of the 62 patients, chronic inflammatory diseases in 17 patients and chronic infection in 13 patients. No cause was determined in 12 patients. Multiple myeloma was present in 5 patients with primary amyloidosis. At the time of diagnosis with amyloidosis, 19 patients were stage 1, 15 stage 2, 5 stage 3A, 12 stage 3B, 10 stage 4 and 8 stage 5. The baseline hemoglobin, serum albumin, creatinine, sodium, potassium, calcium, phosphorus, AST, ALT, PTH, SAA, CRP levels, average daily urinary protein excretion and baseline GFR values were not significantly different in primary and secondary amyloidosis patients. The treatment was medical in 62.3% of the patients, dialysis in 31.9% and renal transplantation in 5.8%.CONCLUSION: The reliability of renal biopsy in the diagnosis of amyloidosis is high. However, genetic studies for the diagnosis of idiopathic cases and special histological staining methods should be considered.
  • Publication
    Correlation between arterial stiffness and inflammatory markers in autosomal dominant polycystic kidney disease patients with preserved renal function
    (Springer, 2015-07-01) Gül, Cuma Bülent; Yıldız, Abdülmecit; Ersoy, Alparslan; Kahvecioğlu, Serdar; Asiltaş, Burak; Yıldırım, Fatih; Ermurat, Selime; Sağ, Saim; Oruç, Ayşegül; Güllülü, Sumeyye; Güllülü, Mustafa; YILDIZ, ABDULMECİT; ERSOY, ALPARSLAN; Asıltaş, Burak; YILDIRIM, FATİH; Ermurat, Selime; Sağ, Saim; ORUÇ, AYŞEGÜL; GÜLLÜLÜ, NAZMİYE SÜMEYYE; GÜLLÜLÜ, MUSTAFA; Tıp Fakültesi; Biyokimya Ana Bilim Dalı; 0000-0003-2467-9356; 0000-0002-0342-9692; 0000-0002-3090-1585; 0000-0001-8404-8252; HIG-9032-2022; AAH-5054-2021; JCN-7114-2023; AAH-4002-2021; ABE-4424-2022; AAW-9185-2020; EKV-7386-2022; EXG-3181-2022; CTG-8811-2022
    To evaluate the association between arterial stiffness and inflammatory markers including C-reactive protein (CRP), pentraxin 3 (PTX3) and neutrophil-to-lymphocyte ratio (NLR) in autosomal dominant polycystic kidney disease (ADPKD) patients with preserved renal function.A total of 52 ADPKD patients [mean (SD) age 38.2 (12.8) years, 69.2 % were females] with preserved renal function and 25 healthy volunteers [mean (SD) age 35.5 (6.5) years, 48.0 % were females] were included. Data on patient characteristics, blood biochemistry, inflammatory markers [PTX3 (pg/mL), CRP (mg/dL) and NLR] and arterial stiffness [large artery elasticity index (LAEI) (mL/mmHg x 10) and small artery elasticity index (SAEI) (mL/mmHg x 100)] were recorded in patient and control groups. Correlation between inflammatory markers and arterial stiffness parameters was analysed in patients.Overall, 42.3 % of ADPKD patients were hypertensive and 44.4 % were receiving renin-angiotensin-aldosterone system (RAAS) blockade therapy. Median levels for PTX3 [442.0 (20.0-4140.0) pg/mL vs. 220.5 (14.7-393.0) pg/mL, p < 0.001] and SAEI [4.90 (1.60-11.80) mL/mmHg x 100 vs. 6.45 (2.80-15.70) mL/mmHg x 10, p = 0.013] were significantly higher in ADPKD patients than in controls. PTX3 and CRP were not correlated with arterial elasticity, while NLR was significantly correlated with LAEI negatively (Rho = -0.278, p = 0.042).In conclusion, our findings revealed increased PTX3 levels and reduced SAEI in patients as compared with controls, while no correlation between inflammatory markers studied and the small artery elasticity.
  • Publication
    Paricalcitol protects peritoneal membrane function in encapsulating peritoneal sclerosis
    (Türk Nefroloji Diyaliz Transplantasyon Dergisi, 2016-01-01) Gül, Cuma Bülent; Yıldız, Abdülmecit; Vuruşkan, Berna; Gül, Özen Öz; Oruç, Ayşegül; Aktaş, Nimet; Ersoy, Alparslan; Güllülü, Mustafa; Dilek, Kamil; Yavuz, Mahmut; Yurtkuran, Mustafa Abbas; YILDIZ, ABDULMECİT; AYTAÇ VURUŞKAN, BERNA; ÖZ GÜL, ÖZEN; ORUÇ, AYŞEGÜL; ERSOY, ALPARSLAN; GÜLLÜLÜ, MUSTAFA; DİLEK, KAMİL; YAVUZ, MAHMUT; Yurtkuran, Mustafa Abbas; Tıp Fakültesi; Endokrinoloji ve Metabolizma Ana Bilim Dalı; 0000-0002-0710-0923 ; 0000-0002-0342-9692; HIG-9032-2022; AAH-9746-2021; AAI-1005-2021; AAH-4002-2021; AAH-5054-2021; JGS-9425-2023; EUF-5229-2022; EHM-7377-2022; IPP-3337-2023
    OBJECTIVE: The most lethal complication of peritoneal dialysis is encapsulating peritoneal sclerosis (EPS), which develops as a result of epithelio-mesenchymal transformation (EMT) and known fibrotic processes. Paricalcitol has previously been shown to inhibit both EMT and fibrosis. We investigated the effect of paricalcitol on EPS.MATERIAL and METHODS: Forty non-uremic albino Wistar rats divided into four groups of equal numbers. The first group was administered 2 mL saline intraperitoneally (IP) and the second group was administered 2 mL of 200 gram chlorhexidine gluconate (CG) (0.1%) dissolved in saline and ethanol (15%) IP. The treatment groups received CG for three weeks in addition to subcutaneous paricalcitol at a dose of 0.2 mcg/kg/day to the third group and 0.4 mcg/kg/day to the fourth group. A one-hour peritoneal equilibration test was performed with 25 mL 3.86% PD solution at the end of the study. Peritoneal membrane and intracardiac blood samples were obtained.RESULTS: D/P urea was significantly low in both treatment groups when compared to group 2 (p<0.05). Paricalcitol co-treatment recovered ultrafitration failure and peritoneal membrane thickness was better paricalcitol groups but there was no statistically significant difference between the groups. Serum calcium, phosphorus and parathyroid hormone levels were similar in all groups.CONCLUSION: Paricalcitol can be effective in the protection of peritoneal functions.
  • Publication
    Lower gastrointestinal tract hemorrhage due to ectopic pancreatic tissue in a renal transplant recipient: : A case report
    (Elsevier, 2002-06-01) Ersoy, Alpaslan; Yavuz, M; Tokyay, R; Yerci, Ömer; Kıyıcı, Murat; Usta, M; Güllülü, Mustafa; Dilek, Kamil; Oktay, B; Yurtkuran, Merih; ERSOY, ALPARSLAN; Yavuz, M; Tokyay, R; YERCİ, ÖMER; KIYICI, MURAT; Usta, M; GÜLLÜLÜ, MUSTAFA; DİLEK, KAMİL; Oktay, B; Yurtkuran, M.; Uludağ Tıp Fakültesi; Tıp Fakültesi; Nefroloji Bölümü; 0000-0002-3208-6211; AAH-5054-2021; AAI-4213-2021; IHY-2104-2023; DZX-1258-2022; EIS-5114-2022; GGE-6952-2022; JGS-9425-2023; EUU-1912-2022; FRV-0139-2022; EGT-2006-2022